SE9901572D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9901572D0
SE9901572D0 SE9901572A SE9901572A SE9901572D0 SE 9901572 D0 SE9901572 D0 SE 9901572D0 SE 9901572 A SE9901572 A SE 9901572A SE 9901572 A SE9901572 A SE 9901572A SE 9901572 D0 SE9901572 D0 SE 9901572D0
Authority
SE
Sweden
Prior art keywords
compounds
solvates
pharmaceutically acceptable
new compounds
carboxypeptidase
Prior art date
Application number
SE9901572A
Other languages
English (en)
Swedish (sv)
Inventor
Marcel Linschoten
Magnus Polla
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9901572A priority Critical patent/SE9901572D0/xx
Publication of SE9901572D0 publication Critical patent/SE9901572D0/xx
Priority to ARP000102084A priority patent/AR023819A1/es
Priority to ARP000102082A priority patent/AR028826A1/es
Priority to MYPI20001884A priority patent/MY126962A/en
Priority to SK1566-2001A priority patent/SK15662001A3/sk
Priority to EP00925845A priority patent/EP1181048B1/en
Priority to AU44472/00A priority patent/AU763772B2/en
Priority to EEP200100573A priority patent/EE200100573A/xx
Priority to US09/600,659 priority patent/US6974800B1/en
Priority to PL356119A priority patent/PL203505B1/pl
Priority to HK02104304.1A priority patent/HK1042493A1/zh
Priority to ES00925845T priority patent/ES2335383T3/es
Priority to RU2001128158/15A priority patent/RU2242992C2/ru
Priority to EEP200100578A priority patent/EE200100578A/xx
Priority to KR1020017014009A priority patent/KR100725206B1/ko
Priority to NZ515063A priority patent/NZ515063A/en
Priority to TR2001/03144T priority patent/TR200103144T2/xx
Priority to CA002371217A priority patent/CA2371217A1/en
Priority to MXPA01011044A priority patent/MXPA01011044A/es
Priority to CN00809484A priority patent/CN1358187A/zh
Priority to HU0202379A priority patent/HUP0202379A3/hu
Priority to JP2000615036A priority patent/JP2002543148A/ja
Priority to SK1565-2001A priority patent/SK15652001A3/sk
Priority to JP2000615381A priority patent/JP4270759B2/ja
Priority to TW089108401A priority patent/TWI232106B/zh
Priority to IL14595300A priority patent/IL145953A0/xx
Priority to HU0201615A priority patent/HUP0201615A3/hu
Priority to IL14595100A priority patent/IL145951A0/xx
Priority to AT00925845T priority patent/ATE447964T1/de
Priority to KR1020017014014A priority patent/KR20020010631A/ko
Priority to CZ20013931A priority patent/CZ20013931A3/cs
Priority to EP00925844A priority patent/EP1180099A1/en
Priority to TR2001/03151T priority patent/TR200103151T2/xx
Priority to PCT/SE2000/000847 priority patent/WO2000066152A1/en
Priority to CZ20013932A priority patent/CZ20013932A3/cs
Priority to PL00356140A priority patent/PL356140A1/xx
Priority to DE60043297T priority patent/DE60043297D1/de
Priority to AU44471/00A priority patent/AU4447100A/en
Priority to BR0010256-3A priority patent/BR0010256A/pt
Priority to MXPA01011043A priority patent/MXPA01011043A/es
Priority to US09/600,660 priority patent/US7354895B1/en
Priority to CNB008071284A priority patent/CN100518820C/zh
Priority to HK02104301.4A priority patent/HK1042442B/en
Priority to BR0010255-5A priority patent/BR0010255A/pt
Priority to PCT/SE2000/000846 priority patent/WO2000066550A1/en
Priority to CA002371215A priority patent/CA2371215A1/en
Priority to ZA200108966A priority patent/ZA200108966B/en
Priority to ZA200108967A priority patent/ZA200108967B/en
Priority to NO20015308A priority patent/NO20015308L/no
Priority to IS6141A priority patent/IS6141A/is
Priority to IS6140A priority patent/IS6140A/is
Priority to NO20015374A priority patent/NO20015374D0/no
Priority to US11/293,060 priority patent/US7423012B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
SE9901572A 1999-05-03 1999-05-03 New compounds SE9901572D0 (sv)

Priority Applications (53)

Application Number Priority Date Filing Date Title
SE9901572A SE9901572D0 (sv) 1999-05-03 1999-05-03 New compounds
ARP000102084A AR023819A1 (es) 1999-05-03 2000-04-28 FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
ARP000102082A AR028826A1 (es) 1999-05-03 2000-04-28 Compuestos que inhiben carboxipeptidasas, un proceso para su preparacion, una formulacion farmaceutica que los contiene y uso de los mismos para la fabricacion de un medicamento
MYPI20001884A MY126962A (en) 1999-05-03 2000-05-02 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
SK1566-2001A SK15662001A3 (sk) 1999-05-03 2000-05-03 Nové zlúčeniny
EP00925845A EP1181048B1 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
AU44472/00A AU763772B2 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase U and a thrombin inhibitor
EEP200100573A EE200100573A (et) 1999-05-03 2000-05-03 Uued ühendid, nende valmistamise meetod ning kasutamine
US09/600,659 US6974800B1 (en) 1999-05-03 2000-05-03 Formulations comprising an inhibitor of carboxypeptidase U and A thrombin inhibitor
PL356119A PL203505B1 (pl) 1999-05-03 2000-05-03 Preparat farmaceutyczny zawieraj acy inhibitor karboksypeptydazy U i inhibitor trombiny, zestaw sk ladników i zastosowanie preparatu farmaceutycznego
HK02104304.1A HK1042493A1 (zh) 1999-05-03 2000-05-03 新的化合物
ES00925845T ES2335383T3 (es) 1999-05-03 2000-05-03 Una formulacion farmaceutica que contiene un inhibidor de carboxipeptidasa y un inhibidor de trombina.
RU2001128158/15A RU2242992C2 (ru) 1999-05-03 2000-05-03 Фармацевтический препарат, содержащий ингибитор карбоксипептидазы u и ингибитор тромбина
EEP200100578A EE200100578A (et) 1999-05-03 2000-05-03 Karboksüpeptidaasi U inhibiitorit ja trombiini inhibiitorit sisaldav ravimpreparaat
KR1020017014009A KR100725206B1 (ko) 1999-05-03 2000-05-03 카르복시펩티다제 ｕ 억제제 및 트롬빈 억제제를 함유하는제약 제제
NZ515063A NZ515063A (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase U and a thrombin inhibitor
TR2001/03144T TR200103144T2 (tr) 1999-05-03 2000-05-03 Yeni bileşikler
CA002371217A CA2371217A1 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
MXPA01011044A MXPA01011044A (es) 1999-05-03 2000-05-03 Formulacion farmaceutica que contiene un inhibidor de carboxipeptidasa u y un inhibidor de trombina..
CN00809484A CN1358187A (zh) 1999-05-03 2000-05-03 新的化合物
HU0202379A HUP0202379A3 (en) 1999-05-03 2000-05-03 New compounds, process for producing them and pharmaceutical compositions containing them
JP2000615036A JP2002543148A (ja) 1999-05-03 2000-05-03 カルボキシペプチダーゼｕ阻害剤とトロンビン阻害剤とを含有する医薬製剤
SK1565-2001A SK15652001A3 (sk) 1999-05-03 2000-05-03 Farmaceutický prípravok obsahujúci inhibítor karboxypeptidázy U a inhibítor trombínu
JP2000615381A JP4270759B2 (ja) 1999-05-03 2000-05-03 新規化合物
TW089108401A TWI232106B (en) 1999-05-03 2000-05-03 Pharmaceutical compositions and kits of parts for the treatment of a patient suffering from or susceptible to a condition in which inhibition of thrombin and/or inhibition of carboxypeptidase U are required or desired
IL14595300A IL145953A0 (en) 1999-05-03 2000-05-03 A new inhibitor of carboxypeptidase u
HU0201615A HUP0201615A3 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
IL14595100A IL145951A0 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
AT00925845T ATE447964T1 (de) 1999-05-03 2000-05-03 Eine pharmazeutische formulierung, enthaltend einen inhibitor der carboxypeptidase a und einen thrombin-inhibitor
KR1020017014014A KR20020010631A (ko) 1999-05-03 2000-05-03 신규 화합물
CZ20013931A CZ20013931A3 (cs) 1999-05-03 2000-05-03 Nové sloučeniny
EP00925844A EP1180099A1 (en) 1999-05-03 2000-05-03 New compounds
TR2001/03151T TR200103151T2 (tr) 1999-05-03 2000-05-03 Karboksipeptidaz U inhibitörü ile trombin inhibitörünü içeren farmasötik bir formülasyon.
PCT/SE2000/000847 WO2000066152A1 (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
CZ20013932A CZ20013932A3 (cs) 1999-05-03 2000-05-03 Farmaceutický prostředek obsahující inhibitor karboxyperoxidasy U a inhibitor thrombinu
PL00356140A PL356140A1 (en) 1999-05-03 2000-05-03 New compounds
DE60043297T DE60043297D1 (de) 1999-05-03 2000-05-03 Eine pharmazeutische formulierung, enthaltend einen inhibitor der carboxypeptidase a und einen thrombin-inhibitor
AU44471/00A AU4447100A (en) 1999-05-03 2000-05-03 New compounds
BR0010256-3A BR0010256A (pt) 1999-05-03 2000-05-03 Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kit de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários
MXPA01011043A MXPA01011043A (es) 1999-05-03 2000-05-03 Compuestos novedosos que inhiben las carboxipeptidasas basicas.
US09/600,660 US7354895B1 (en) 1999-05-03 2000-05-03 Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors
CNB008071284A CN100518820C (zh) 1999-05-03 2000-05-03 含有羧肽酶u抑制剂和凝血酶抑制剂的药物制剂
HK02104301.4A HK1042442B (en) 1999-05-03 2000-05-03 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor
BR0010255-5A BR0010255A (pt) 1999-05-03 2000-05-03 Formulação farmacêutica, kit de partes, método para tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da trombina e/ou inibição da carboxipeptidase u são requeridas ou desejadas, e, uso de uma formulação
PCT/SE2000/000846 WO2000066550A1 (en) 1999-05-03 2000-05-03 New compounds
CA002371215A CA2371215A1 (en) 1999-05-03 2000-05-03 New compounds
ZA200108966A ZA200108966B (en) 1999-05-03 2001-10-30 A pharmaceutical formulation containing an inhibitor of carboxypeptidase U and a thrombin inhibitor.
ZA200108967A ZA200108967B (en) 1999-05-03 2001-10-30 New compounds.
NO20015308A NO20015308L (no) 1999-05-03 2001-10-30 En farmasoytisk formulering som inneholder en inhibitor av karboksypeptidase U og A trombininhibitor
IS6141A IS6141A (is) 1999-05-03 2001-11-01 Ný efnasambönd
IS6140A IS6140A (is) 1999-05-03 2001-11-01 Lyfjablanda sem inniheldur hemil karboxýpeptíðasaU og þrombínhemil
NO20015374A NO20015374D0 (no) 1999-05-03 2001-11-02 Nye forbindelser
US11/293,060 US7423012B2 (en) 1999-05-03 2005-12-02 Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901572A SE9901572D0 (sv) 1999-05-03 1999-05-03 New compounds

Publications (1)

Publication Number Publication Date
SE9901572D0 true SE9901572D0 (sv) 1999-05-03

Family

ID=20415425

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9901572A SE9901572D0 (sv) 1999-05-03 1999-05-03 New compounds

Country Status (23)

Country Link
US (2) US7354895B1 (https=)
EP (1) EP1180099A1 (https=)
JP (1) JP4270759B2 (https=)
KR (1) KR20020010631A (https=)
CN (1) CN1358187A (https=)
AR (1) AR028826A1 (https=)
AU (1) AU4447100A (https=)
BR (1) BR0010256A (https=)
CA (1) CA2371215A1 (https=)
CZ (1) CZ20013931A3 (https=)
EE (1) EE200100573A (https=)
HK (1) HK1042493A1 (https=)
HU (1) HUP0202379A3 (https=)
IL (1) IL145953A0 (https=)
IS (1) IS6141A (https=)
MX (1) MXPA01011043A (https=)
NO (1) NO20015374D0 (https=)
PL (1) PL356140A1 (https=)
SE (1) SE9901572D0 (https=)
SK (1) SK15662001A3 (https=)
TR (1) TR200103144T2 (https=)
WO (1) WO2000066550A1 (https=)
ZA (2) ZA200108966B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100681632B1 (ko) * 1999-09-14 2007-02-09 메이지 세이카 가이샤 리미티드 카르복시펩티다아제 ｂ 저해활성을 갖는 포스폰산 유도체
PL361054A1 (en) * 2000-08-17 2004-09-20 Pfizer Inc. Substituted imidazoles as tafia inhibitors
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
WO2003061653A1 (en) 2002-01-22 2003-07-31 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
EP1467731A1 (en) * 2002-01-22 2004-10-20 Pfizer Limited 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
EP1497300A2 (en) * 2002-03-21 2005-01-19 Schering Aktiengesellschaft Plasma carboxypeptidase b inhibitors
NZ592764A (en) 2008-10-29 2012-08-31 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
CN113395996B (zh) 2019-02-08 2024-05-28 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
CN111110837B (zh) * 2020-01-06 2022-11-25 中国人民解放军陆军军医大学 一种羧肽酶抑制剂在制备预防重症致死性轮状病毒感染药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516307A (en) * 1949-01-06 1950-07-25 Gen Mills Inc Vinyl resins plasticized with cyano esters
US4560680A (en) * 1982-03-15 1985-12-24 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4849414A (en) * 1986-06-11 1989-07-18 E. R. Squibb & Sons, Inc. Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors
FR2610951B1 (fr) * 1987-02-17 1989-05-05 Aerospatiale Armature tissee pour materiau composite
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
JPH07502507A (ja) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
JP3440305B2 (ja) * 1997-04-02 2003-08-25 高砂香料工業株式会社 ７−（ｎ−置換アミノ）−２−フェニルヘプタン酸 エステル誘導体及び該誘導体の製造方法
PT973512E (pt) 1997-02-27 2004-07-30 Wyeth Corp N-hidroxi-2-(alquil, aril ou heteroaril sulfanil, sulfinilou sulfonil)-alquil, aril ou heteroarilamidas substituidas na posicao 3 como inibidores de metaloproteinases da matriz
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
KR100681632B1 (ko) * 1999-09-14 2007-02-09 메이지 세이카 가이샤 리미티드 카르복시펩티다아제 ｂ 저해활성을 갖는 포스폰산 유도체

Also Published As

Publication number Publication date
JP2002543179A (ja) 2002-12-17
MXPA01011043A (es) 2002-06-04
JP4270759B2 (ja) 2009-06-03
CA2371215A1 (en) 2000-11-09
EE200100573A (et) 2003-02-17
AR028826A1 (es) 2003-05-28
SK15662001A3 (sk) 2002-09-10
ZA200108967B (en) 2003-01-30
CN1358187A (zh) 2002-07-10
US7354895B1 (en) 2008-04-08
NO20015374L (no) 2001-11-02
WO2000066550A8 (en) 2001-01-25
HK1042493A1 (zh) 2002-08-16
ZA200108966B (en) 2003-01-30
TR200103144T2 (tr) 2004-11-22
EP1180099A1 (en) 2002-02-20
KR20020010631A (ko) 2002-02-04
WO2000066550A1 (en) 2000-11-09
HUP0202379A3 (en) 2003-04-28
IL145953A0 (en) 2002-11-10
IS6141A (is) 2001-11-01
HUP0202379A2 (hu) 2002-12-28
BR0010256A (pt) 2002-02-13
AU4447100A (en) 2000-11-17
US20060079484A1 (en) 2006-04-13
CZ20013931A3 (cs) 2002-04-17
PL356140A1 (en) 2004-06-14
NO20015374D0 (no) 2001-11-02
US7423012B2 (en) 2008-09-09

Similar Documents

Publication Publication Date Title
SE9901573D0 (sv) New compounds
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
SE0202462D0 (sv) Novel use
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
CY1107753T1 (el) 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
SE0002476D0 (sv) New compounds
SE0102440D0 (sv) New compound
SE9901572D0 (sv) New compounds
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
HU9802897D0 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
MY133438A (en) Morpholinobenzamide salts
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
ATE301997T1 (de) Antivirale therapie
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor
TW200500330A (en) Pharmaceutical composition
UY27855A1 (es) Compuestos quimicos
DE60104288D1 (de) Antivirale therapie